Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).-Reference-Cited by-同舟云学术

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

Published:2018-05-20 Issue:15_suppl Volume:36 Page:105-105
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Paz-Ares Luis G.¹,Luft Alexander²,Tafreshi Ali³,Gumus Mahmut⁴,Mazieres Julien⁵,Hermes Barbara⁶,Cay Senler Filiz⁷,Fülöp Andrea⁸,Rodriguez-Cid Jeronimo⁹,Sugawara Shunichi¹⁰,Cheng Ying¹¹,Novello Silvia¹²,Halmos Balazs¹³,Shentu Yue¹⁴,Kowalski Dariusz¹⁵

Affiliation:

1. University Hospital 12 de October, Madrid, Spain;

2. Leningrad Regional Clinical Hospital, St. Petersburg, Russia;

3. Austin Health, Waterways, Australia;

4. Kartal Research and Training Hospital, Istanbul, Turkey;

5. Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, France;

6. Universitätskinikum Tübingen, Tuebingen, Germany;

7. Ankara University Department of Medical Oncology, Ankara, Turkey;

8. Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary, Budapest, Hungary;

9. Oncology Center, Medica Sur Hospital, Mexico City, Mexico;

10. Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan;

11. Department of Oncology, Cancer Hospital of Jilin Province, Changchun, China;